<?xml version='1.0' encoding='utf-8'?>
<document id="31756280"><sentence text="Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review."><entity charOffset="53-63" id="DDI-PubMed.31756280.s1.e0" text="tacrolimus" /><entity charOffset="68-79" id="DDI-PubMed.31756280.s1.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.31756280.s1.e0" e2="DDI-PubMed.31756280.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31756280.s1.e0" e2="DDI-PubMed.31756280.s1.e1" /></sentence><sentence text="Clinical use of fluconazole against fungal infections in renal transplant patients is complicated by the potentially marked and unpredictable drug-drug interactions (DDIs)"><entity charOffset="16-27" id="DDI-PubMed.31756280.s2.e0" text="fluconazole" /></sentence><sentence text=" We report a case of tacrolimus-fluconazole DDI in a stable renal transplant recipient and describe the mechanism, magnitude and duration of this DDI through a literature review" /><sentence text="" /><sentence text="A 38-year-old woman experienced a 9" /><sentence text="1-fold increase in dose-normalized tacrolimus trough level (trough concentration/weight-normalized daily dose) and an 87% decrease in weight-normalized daily dose (daily dose/body weight) in the treatment of documented Candida albicans oesophagitis by fluconazole"><entity charOffset="35-45" id="DDI-PubMed.31756280.s6.e0" text="tacrolimus" /><entity charOffset="252-263" id="DDI-PubMed.31756280.s6.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.31756280.s6.e0" e2="DDI-PubMed.31756280.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31756280.s6.e0" e2="DDI-PubMed.31756280.s6.e1" /></sentence><sentence text=" After discontinuation of fluconazole for 161Â day, a 26% reduction in weight-normalized daily dose was required to maintain therapeutic exposure"><entity charOffset="26-37" id="DDI-PubMed.31756280.s7.e0" text="fluconazole" /></sentence><sentence text="" /><sentence text="Oral fluconazole has a more significant impact on its drug interactions with tacrolimus than intravenous fluconazole"><entity charOffset="5-16" id="DDI-PubMed.31756280.s9.e0" text="fluconazole" /><entity charOffset="77-87" id="DDI-PubMed.31756280.s9.e1" text="tacrolimus" /><entity charOffset="105-116" id="DDI-PubMed.31756280.s9.e2" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.31756280.s9.e0" e2="DDI-PubMed.31756280.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31756280.s9.e0" e2="DDI-PubMed.31756280.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31756280.s9.e0" e2="DDI-PubMed.31756280.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31756280.s9.e1" e2="DDI-PubMed.31756280.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31756280.s9.e1" e2="DDI-PubMed.31756280.s9.e2" /></sentence><sentence text=" Gene screening for CYP3A5 6986 A&gt;G and ABCB1 3435 C&gt;T in organ transplant recipients may help in preventing DDI and facilitating tacrolimus dose adjustment"><entity charOffset="130-140" id="DDI-PubMed.31756280.s10.e0" text="tacrolimus" /></sentence><sentence text="" /></document>